Tevogen Bio Teams Up With Microsoft to Develop Treatments for Human Papilloma Virus

MT Newswires Live11-05 23:45

Tevogen Bio Holdings (TVGN) said Tuesday it's artificial intelligence initiative Tevogen.AI has launched a partnership with Microsoft (MSFT) to investigate potential treatments for human papilloma virus.

Tevogen said it has developed a dataset of proteins from the HPV genome and is identifying cytotoxic T-cell targets to choose for a trial for TVGN 920, which will be its first oncology product.

"By leveraging Microsoft's cutting-edge AI and cloud technologies, we're able to accelerate our target identification and pre-clinical processes in ways that weren't previously possible," said Tevogen.AI Chief Information Officer and Head Mittul Mehta.

Financial details about the project weren't provided.

Price: 1.91, Change: -0.05, Percent Change: -2.81

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment